Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of March 31, 2017				Fair Value Measurements
	Carrying		Fair		As of March 31, 2017
	Amount		Value		Level 1		Level 2			Level 3
Assets:
Cash and cash equivalents:
Cash	$	7,126	$	7,126	$	7,126	$	-	#	$	-
	$	7,126	$	7,126	$	7,126	$	-		$	-
Liabilities:
Contingent consideration:
Asuragen	$	1,561	$	1,561	$	-	$	-		$	1,561
Derivative liability:
Embedded conversion derivative	$	51	$	51	$	-	$	-		$	51
	$	1,612	$	1,612	$	-	$	-		$	1,612

As of December 31, 2016					Fair Value Measurements
	Carrying		Fair			As of December 31, 2016
	Amount		Value			Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents:
Cash	$	602	$	602		$	602	$	-	$	-
	$	602	$	602		$	602	$	-	$	-
Liabilities:
Contingent consideration:
Asuragen	$	1,545	$	1,545		$	-	$	-	$	1,545
RedPath		5,969		5,969			-		-		5,969
	$	7,514	$	7,514		$	-	$	-	$	7,514

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the contingent consideration and also the embedded conversion option from continuing operations from January 1, 2017 to March 31, 2017 is as follows:

	2017
										Cancellation
			Initial							of Obligation/			Mark to
	January 1,		Liability		Payments			Accretion		Conversions			Market		March 31,
Asuragen	$	1,545			$	(25	)	$	41	$	-		$	-	$	1,561
Redpath		5,969				-			-		(5,969	)		-		-
Embedded conversion option		-		208		-					(199	)		42		51
	$	7,514	$	208	$	(25	)	$	41	$	(6,168	)	$	42	$	1,612

Schedule of Assumptions Used in Black-Scholes Option Pricing Model

The following table sets forth the assumptions used in the Black-Scholes Option Pricing Model to estimate the fair value of the embedded conversion option derivative liability as of March 31, 2017:

	March 31, 2017

Market Price	$	2.63
Exercise Price	$	2.44
Risk-free interest rate		0.99	%
Expected volatility		234.05	%
Expected life in years		1.25
Expected dividend yield		0.00